I.B.F. MANAGEMENT LTD.

Thesis

Israel Biotech Fund (IBF) is a venture capital firm dedicated to early-stage investments in biotechnology, pharmaceutical, and technology sectors, with a primary focus on Israel and Israeli-related entities. Their core strategy revolves around identifying and nurturing therapeutic assets within Israeli biotech companies, particularly those engaged in drug development and medical diagnostics. IBF exclusively invests in biotech firms advancing drugs towards or into clinical stages, aiming to lead significant investment rounds to facilitate professional clinical program execution. The fund's sector focus includes biotechnology, pharmaceuticals, drug development, medical diagnostics, therapeutic assets, oncology, autoimmune diseases, personalized medicine, and digital health. They prefer early-stage companies at or near clinical stages and concentrate their geographic scope on Israel and Israeli-related companies. Their strategy involves acting as a lead investor in major funding rounds, offering hands-on guidance through a team of venture advisors. IBF's first fund raised $70 million, and their second fund closed at $112 million, indicating substantial investment capacity. The fund was founded in 2014/2015 and is legally known as Israel Biotech Fund (IBF), headquartered in Rehovot, Israel.

Related lists

• Seed-stage Healthcare investors
• Series A Healthcare investors
• Series B Healthcare investors